Oncologic Outcomes and Safety of Neoadjuvant Treatment with Anthracyclines Versus Anthracycline-Free Regimens in HER2-Positive Early Breast Cancer in a Colombian Cancer Center: An Observational, Analytical, Retrospective Study

Alfredo Acevedo-Ramos, Andrea Zuluaga-Liberato, Sandra E. Díaz-Casas

Open source

DOI
10.3390/cancers17193190
Published
2025-09-30
Container
Cancers
Publisher
MDPI AG
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/cancers17193190,
  title = {Oncologic Outcomes and Safety of Neoadjuvant Treatment with Anthracyclines Versus Anthracycline-Free Regimens in HER2-Positive Early Breast Cancer in a Colombian Cancer Center: An Observational, Analytical, Retrospective Study},
  author = {Alfredo Acevedo-Ramos and Andrea Zuluaga-Liberato and Sandra E. Díaz-Casas},
  year = {2025},
  journal = {Cancers},
  doi = {10.3390/cancers17193190},
  url = {https://doi.org/10.3390/cancers17193190}
}

RIS

TY  - JOUR
TI  - Oncologic Outcomes and Safety of Neoadjuvant Treatment with Anthracyclines Versus Anthracycline-Free Regimens in HER2-Positive Early Breast Cancer in a Colombian Cancer Center: An Observational, Analytical, Retrospective Study
AU  - Alfredo Acevedo-Ramos
AU  - Andrea Zuluaga-Liberato
AU  - Sandra E. Díaz-Casas
PY  - 2025
JO  - Cancers
DO  - 10.3390/cancers17193190
UR  - https://doi.org/10.3390/cancers17193190
ER  - 

APA

Acevedo-Ramos, A., Zuluaga-Liberato, A., & Díaz-Casas, S. E. (2025). Oncologic Outcomes and Safety of Neoadjuvant Treatment with Anthracyclines Versus Anthracycline-Free Regimens in HER2-Positive Early Breast Cancer in a Colombian Cancer Center: An Observational, Analytical, Retrospective Study. Cancers. https://doi.org/10.3390/cancers17193190

Source records